Fingerprint
Dive into the research topics of 'Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients
Anna Sundlöv, Katarina Sjögreen Gleisner, Jan Tennvall, Michael Ljungberg, Carl Fredrik Warfvinge, Kajsa Holgersson, Andreas Hallqvist, Peter Bernhardt, Johanna Svensson
Research output: Contribution to journal › Article › peer-review